A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

PHASE3CompletedINTERVENTIONAL
Enrollment

650

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Bipolar I Disorder
Interventions
DRUG

Aripiprazole

Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.

DRUG

Placebo

Tablets, Oral, 0 mg, Once daily, 8 weeks.

Trial Locations (40)

Unknown

Local Institution, Mesa

Local Institution, La Mesa

Local Institution, La Palma

Local Institution, Long Beach

Local Institution, Redlands

Local Institution, San Diego

Local Institution, Sherman Oaks

Local Institution, Washington D.C.

Local Institution, Coral Springs

Local Institution, Jacksonville

Local Institution, St. Petersburg

Local Institution, Marietta

Local Institution, Edwardsville

Local Institution, Oak Brook

Local Institution, Springfield

Local Institution, Lafayette

Local Institution, Newton

Local Institution, New Orleans

Local Institution, Shreveport

Local Institution, Baltimore

Local Institution, St Louis

Local Institution, Clementon

Local Institution, Albuquerque

Local Institution, Brooklyn

Local Institution, Elmsford

Local Institution, New York

Local Institution, Raleigh

Local Institution, Dayton

Local Institution, Media

Local Institution, Philadelphia

Local Institution, Pittsburgh

Local Institution, Columbia

Local Institution, DeSoto

Local Institution, Houston

Local Institution, Wichita Falls

Local Institution, Salt Lake City

Local Institution, Charlottesville

Local Institution, Midlothian

Local Institution, Bellevue

Local Institution, Charleston

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT00094432 - A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode | Biotech Hunter | Biotech Hunter